1 / 5

Prevention

Prevention. Bacille Calmette Guerin (BCG) Vaccine Live attenuated strain of Mycobacterium bovis ; 1921 Efficacy Clinical trials UK: protective effect of 60 to 80%; Trials elsewhere have shown variable results; efficacy  the closer one gets to the equator

kostya
Télécharger la présentation

Prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prevention • BacilleCalmette Guerin (BCG) Vaccine • Live attenuated strain of Mycobacterium bovis; 1921 • Efficacy • Clinical trials UK: protective effect of 60 to 80%; • Trials elsewhere have shown variable results; efficacy the closer one gets to the equator • Meta-analysis Colditz et al. (1994) = 50 per cent effective • Most important protective benefits are in minimising the risk of death, meningitis and miliary disease in neonates and young children • WHO recommend  given to all children in countries highly endemic for TB Australian Recommendations: 1. Aboriginal neonates in areas of high incidence (e.g. NT, Far North Queensland, N WA & SA) 2. Individuals travelling to or living in areas with  prevalence of TB 3. Neonates born to parents with leprosy or a Fx of leprosy; 4. HCWs who may be at high risk of exposure to drug resistant cases

  2. Very safe • Anaphylactoid reactions (rare); Most common is development of a localised abscess at the site of injection, especially if the vaccination is given too deeply • Immuno-compromised  risk for disseminated BCG infection • C/I: Positive TST of greater than 5-mm diameter in duration; Immunocompromised (HIV, corticosteroids, chemo, malignancies ); Pregnant (?); PHx TB; Febrile; Pt suffers from a generalised skin disease such as eczema and psoariasis Method • Tuberculin skin test (Manoux) is done first (except infants below 6 months where Hx of TB excluded) • C/I if reactive -  risk of severe local inflammation and scarring • Single intradermal injection at the insertion of the deltoid – other sites: risk of keloid formation

  3. Infection Control • Isolation = Negative Pressure Rooms – prevent cross-contaminations from room to room • Generates negative pressure to allow air to flow into the isolation room but not escape from the room • Educate patient about transmission  cover mouth when coughing etc • Masks – special filter masks

  4. Prophylaxis • Screen close contacts with tuberculin test +CXR • Tuberculin +ve, CXR –ve: nothing further • Pt with HIV, no BCG - isoniazidprophylaxis↓risk by 40% • Child with +ve tuberculin test treatment • Tuberculin –ve in children/young adults repeat in 6 wks; administer BCG if still –ve / treatment if +ve • Children <1y with family member with TB - isoniazid6/12 + BCG with strain resistant to isoniazid

More Related